CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletion and exon 21 L858R, are driver oncogenes of non-small cell lung cancer (NSCLC), with EGFR tyrosine kinase inhibitors (TKIs) being effective against EGFR-mutant NSCLC. However, the efficacy of EGFR-TKIs is transien...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Naofumi, Ichihara, Eiki, Kano, Hirohisa, Ando, Chihiro, Morita, Ayako, Nishi, Tatsuya, Okawa, Sachi, Nakasuka, Takamasa, Hirabae, Atsuko, Abe, Masaya, Asada, Noboru, Ninomiya, Kiichiro, Makimoto, Go, Fujii, Masanori, Kubo, Toshio, Ohashi, Kadoaki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654429/
https://www.ncbi.nlm.nih.gov/pubmed/38025818
http://dx.doi.org/10.21037/tlcr-23-99

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654429/
https://www.ncbi.nlm.nih.gov/pubmed/38025818
http://dx.doi.org/10.21037/tlcr-23-99

Ejemplares similares